Early experiences with Suboxone maintenance therapy in Hungary

Neuropsychopharmacologia Hungarica

Volumn 11, Issue 4, 2009, Pages 249-257

  Dementrovics, Zsolt ^a   Farkas, Judit ^a   Csorba, József ^b   Németh, Attila ^c   Mervó, Barbara ^a   Szemelyácz, János ^d   Fleischmann, Eniko ^e   Kassai Farkas, Ákos ^f   Petke, Zsolt ^b   Oroján, Tibor ^g   Rózsa, Sándor ^a   Rigó, Péter ^h   Funk, Sándor ⁱ   Kapitány, Máté ^a   Kollár, Anna ^a   Rácz, József ^j,k  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b Nyírocombining double acute accent Gyula Hospital Drug Outpatient and Prevention Center   (Hungary)

^c Pest County Flór Ferenc Hospital   (Sweden)

^d INDIT Foundation Baranya County Drug Outpatient Center   (Hungary)

^e Pandy County Hospital   (Hungary)

^f Psychiatry Ward   (Hungary)

^g Dr Farkasinszky Terézia Drug Center   (Hungary)

^h Psychiatry Ward   (Hungary)

ⁱ Nyírocombining double acute accent Gyula Hospital Addiction Ward   (Hungary)

^j Blue Point Outpatient and Prevention Centre   (Hungary)

^k INSTITUTE FOR PSYCHOLOGY   (Hungary)

more..

Author keywords

Buprenorphine; Effectiveness; Heroin substitution; Hungary; Maintenance therapy; Naloxone; Suboxone

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; BUPRENORPHINE; NALOXONE; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HUNGARY; MALE; OPIATE ADDICTION; ANXIETY; DEPRESSION; DRUG COMBINATION; DRUG DEPENDENCE TREATMENT; IRRITABILITY; MENTAL STRESS; PSYCHOLOGICAL RATING SCALE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; ANXIETY; BUPRENORPHINE; DEPRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; HUNGARY; IRRITABLE MOOD; MALE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; STRESS, PSYCHOLOGICAL; SUBSTANCE ABUSE TREATMENT CENTERS; TREATMENT OUTCOME;

EID: 77749240464     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Amass, L., Ling, W., Freese, T. E., Reiber, C., Annon, J. J., Cohen, A. J., et al. (2004). Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict, 13 Suppl 1, S42-66.
2. Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M. M., & Mayet, S. (2008). Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev(4), CD004147.
3. Bech, P., Gudex, C., & Johansen, K. S. (1996). The WHO (Ten) Well-Being Index: validation in diabetes. Psychother Psychosom, 65(4), 183-190.
4. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., & Erbaugh, J. (1961). An inventory for measuring depression. Arch Gen Psychiatry, 4, 561-571.
5. Cloninger, C. R., Przybeck, T. R., Svrakic, D. M., & Wetzel, R. D. (1994). The Temperament and Character Inventory (TCI): A guide to its development and use. St Louis, MO: Center for Psychobiology of Personality, Washington University.
6. Cohen, S., Kamarck, T., & Mermelstein, R. (1983). A global measure of perceived stress. J Health Soc Behav, 24(4), 385-396.
7. DuPaul, G. J., Power, T. J., Anastopoulos, A. D., & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press.
8. Faries, D. E., Yalcin, I., Harder, D., & Heiligenstein, J. H. (2001). Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord, 5(2), 107-116.
9. First, M. B., Gibbon, M., Spitzer, R. L., Williams, J. B. W., & Benjamin, L. S. (1997). Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington: American Psychiatric Press.
10. First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1997). Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Washington: American Psychiatric Press.
11. Folkman, S., & Lazarus, R. S. (1988). Manual for the Ways of Coping questionnaire [Research Edition]. Palo Alto, CA: Consulting Psychologists.
12. Gerevich, J., Bacskai, E., Ko, J. & Rozsa, S. (2005). Reliability and validity of the Hungarian version of the European Addiction Severity Index. Psychopathology, 38(6), 301-309.
13. Hamilton, M. (1959). The assessment of anxiety states by rating. Br J Med Psychol, 32(1), 50-55.
14. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol, 6(4), 278-296.
15. Hungarian National Focal Point. (2009). 2009 National Report to the EMCDDA by the Reitox National Focal Point. "Hungary" New developments, trends and in-depth information on selected issues. Budapest: Hungarian National Focal Point.
16. Johnson, R. E., & McCagh, J. C. (2000). Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep, 2(6), 519-526.
17. Kakko, J., Gronbladh, L., Svanborg, K. D., von Wachenfeldt, J., Ruck, C., Rawlings, B., et al. (2007). A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry, 164(5), 797-803.
18. Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci, 9(4), 455-470.
19. Law, F. D., Myles, J. S., Daglish, M. R. C., & Nutt, D. J. (2004). The clinical use of buprenorphine in opiate addiction: evidence and practice. Acta Neuropsychiatrica, 16(5), 246-274.
20. Mammen, K., & Bell, J. (2009). The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother, 10(15), 2537-2544.
21. McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, Grissom, G., et al. (1992). The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat, 9(3), 199-213.
22. Nunes, E. V., Sullivan, M. A., & Levin, F. R. (2004). Treatment of depression in patients with opiate dependence. Biol Psychiatry, 56(10), 793-802.
23. Orman, J. S., & Keating, G. M. (2009a). Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs, 69(5), 577-607.
24. Orman, J. S., & Keating, G. M. (2009b). Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs, 23(10), 899-902.
25. Perczel Forintos, D., Kiss, Z., & Ajtay, G. (Eds.). (2005). Kérdocombining double acute accentívek, becslocombining double acute accentskálák a klinikai pszichológiában. Budapest: Országos Pszichiátriai és Neurológiai Intézet.
26. Rácz, J., Pogány, C., & Máthé- Árvay, N. (2002). Az EuropASI (Addikció Súlyossági Index) magyar nyelvucombining double acute accent változatának reliabilitás- és validitásvizsgálata. Magyar Pszichológiai Szemle, 57(4), 587-603.
27. Rózsa, S., Kállai, J., Osváth, A., & Bánki, M. C. (2005). Temperamentum és karakter: Cloninger pszichobiológiai modellje. A Cloninger-féle temperamentum és karakter kérdocombining double acute accentív felhasználói kézikönyve. Budapest: Medicina Könyvkiadó.
28. Rózsa, S., Purebl, G., Susánszky, É., Kocombining double acute accent, N., Szádóczky, E., Réthelyi, J., et al. (2008). A megküzdés dimenziói: a konfliktusmegoldó kérdocombining double acute accent;ív hazai adaptá ciója. Mentálhigiéné Pszichoszomatika, 7(3), 247-255.
29. Rózsa, S., Szádóczky, E., & Füredi, J. (2001). A beck depresszió kérdocombining double acute accentív rövidített változatának jellemzocombining double acute accenti hazai mintán. Psychiatr Hung, 16(4), 379-397.
30. Rózsa, S., Szádóczky, E., Schmidt, V., & Füredi, J. (2003). A Hamilton Depresszió Skála pszichometriai jellemzocombining double acute accenti depressziós betegek körében. Psychiatr Hung, 18(4), 251-262.
31. Schuster, C. R., Greenwald, M. K., Johanson, C. E., & Heishman, S. J. (1995). Measurement of drug craving during naloxone-precipitated withdrawal in methadone-maintained volunteers. Exp Clin Psychopharmacol, 3(4), 424-431.
32. Sipos, K., Sipos, M., & Spielberger, C. D. (1988). A State-Trait Anxiety Inventory (STAI) magyar változata. In F. Mérei & F. Szakács (Eds.), Pszichodiagnosztikai Vademecum I/2. rész (pp.123-135). Budapest: Tankönyvkiadó.
33. Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970). Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologist Press.
34. Stauder, A., & Konkolÿ Thege, B. (2006). Az Észlelt Stressz Kérdocombining double acute accentív magyar verziójának jellemzocombining double acute accenti. Mentálhigiéné és Pszichoszomatika, 7(3), 203-216.
35. Strain, E. C. (2002). Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain, 18(4 Suppl), S14-27.
36. Susánszky, É., Konkolÿ Thege, B., Stauder, A., & Kopp, M. (2006). A who Jól-lét kérdocombining double acute accentív rövidített (WBI-5) magyar változatának validálása a Hungarostudy 2002 országos lakossági egészségfelmérés alapján. Mentálhigiéné és Pszichoszomatika, 7(3), 247-255.
37. Tiffany, S. T., Fields, L., Singleton, E., Haertzen, C., & Henning-field, J. E. (1995). The development of a heroin craving questionnaire. Unpublished manuscript.
38. Van den Brink, W., & Haasen, C. (2006). Evidenced-based treatment of opioid-dependent patients. Can J Psychiatry, 51(10), 635-646.
39. Whitley, S. D., Kunins, H. V., Arnsten, J. H., & Gourevitch, M. N. (2007). Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. J Subst Abuse Treat, 33(1), 85-90.
40. World Health Organization. (2009). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization.